1. PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1–AKT–mTOR/Bcl2 pathway
- Author
-
Hua Zhang, Shi-Jia Zhou, Chen-Feng Shen, Yong-Nan Zhou, Cai-Yun Wu, Meng-Yu Zhu, Qi-Meng Yu, Annoor Awadasseid, Yan-Ling Wu, and Wen Zhang
- Subjects
Biphenyl derivative ,PD-L1 ,GSK-3β ,non-immune pathway ,apoptosis ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Recent studies on biphenyl-containing compounds, a type of PD-1/PD-L1 blocker which binds to PD-L1 and induces dimerisation, have focussed on its immune function. Herein, 10 novel biphenyl derivatives were designed and synthesised. The results of the CCK-8 showed that compounds have different anti-tumour activities for tumour cells in the absence of T cells. Particularly, 12j–4 can significantly induce the apoptosis of MDA-MB-231 cells (IC50 = 2.68 ± 0.27 μM). In further studies, 12j–4 has been shown to prevent the phosphorylation of AKT by binding to cytoplasmic PD-L1, which induces apoptosis in MDA-MB-231 cells through non-immune pathways. The inhibition of AKT phosphorylation restores the activity of GSK-3β, ultimately resulting in the degradation of PD-L1. Besides, in vivo study indicated that 12j–4 repressed tumour growth in nude mice. As these biphenyls exert their anti-tumour effects mainly through non-immune pathways, they are worthy of further study as PD-L1 inhibitors.
- Published
- 2023
- Full Text
- View/download PDF